Humana Inc. (NYSE:HUM) Shares Acquired by Central Pacific Bank Trust Division

Central Pacific Bank Trust Division lifted its stake in Humana Inc. (NYSE:HUM) by 110.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 2,950 shares of the insurance provider’s stock after acquiring an additional 1,550 shares during the quarter. Central Pacific Bank Trust Division’s holdings in Humana were worth $748,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Creative Financial Designs Inc. ADV raised its position in Humana by 244.0% in the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after purchasing an additional 61 shares during the period. Atwood & Palmer Inc. purchased a new stake in shares of Humana in the 3rd quarter valued at $29,000. Ashton Thomas Securities LLC acquired a new position in Humana during the 3rd quarter worth about $31,000. Your Advocates Ltd. LLP boosted its holdings in Humana by 81.8% during the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after acquiring an additional 45 shares during the period. Finally, Hollencrest Capital Management acquired a new position in Humana in the 2nd quarter valued at about $40,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Insider Buying and Selling

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now owns 8,181 shares in the company, valued at approximately $2,096,463.06. This represents a 31.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.29% of the company’s stock.

Humana Price Performance

Shares of NYSE HUM opened at $262.47 on Friday. The stock has a market cap of $31.60 billion, a P/E ratio of 23.25, a P/E/G ratio of 2.12 and a beta of 0.53. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $471.37. The stock has a 50 day moving average of $272.56 and a two-hundred day moving average of $314.60. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. The firm had revenue of $29.30 billion during the quarter, compared to analysts’ expectations of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. On average, research analysts forecast that Humana Inc. will post 16.14 earnings per share for the current year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be paid a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.35%. The ex-dividend date of this dividend is Tuesday, December 31st. Humana’s dividend payout ratio (DPR) is presently 31.36%.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Barclays increased their price target on shares of Humana from $250.00 to $253.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Oppenheimer decreased their price target on shares of Humana from $400.00 to $280.00 and set an “outperform” rating for the company in a research report on Thursday, October 3rd. Royal Bank of Canada cut their price objective on Humana from $400.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. UBS Group decreased their target price on Humana from $380.00 to $250.00 and set a “neutral” rating for the company in a report on Friday, October 4th. Finally, Deutsche Bank Aktiengesellschaft cut their price target on Humana from $349.00 to $250.00 and set a “hold” rating on the stock in a report on Thursday, October 3rd. Twenty analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $300.50.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.